Telix pharmaceutical/$TLX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Telix pharmaceutical

Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.

Ticker

$TLX
Primary listing

Industry

Biotechnology

Headquarters

North Melbourne, Australia

Employees

423

TLX Metrics

BasicAdvanced
$4.7B
146.12
$0.10
2.43
-

Bulls say / Bears say

Telix Pharmaceuticals reported a record revenue of $517 million in FY2024, marking a 55% increase, driven by the expansion of its cancer imaging portfolio. (stocktitan.net)
Wedbush initiated coverage on Telix with an 'outperform' rating and a price target of $22.00, indicating confidence in the company's growth prospects. (webull.com)
William Blair raised its FY2025 earnings estimate for Telix to $0.83 per share, reflecting optimism about the company's financial performance. (etfdailynews.com)
William Blair reduced its FY2026 earnings estimate for Telix to $1.03 per share, down from $1.05, suggesting potential concerns about future earnings growth. (defenseworld.net)
The stock has experienced volatility, with a 52-week high of $30.36 and a low of $13.61, indicating potential instability in investor sentiment. (cnbc.com)
Despite strong revenue growth, the company's reliance on a limited product portfolio could pose risks if competitors introduce superior alternatives or if regulatory challenges arise.
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $TLX

Sign up or log in to buy
Capital at risk
Market openADR

Upcoming events

No upcoming events
FAQs